Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos
Autor(a) principal: | |
---|---|
Data de Publicação: | 1999 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0102-35861999000600002 http://repositorio.unifesp.br/handle/11600/860 |
Resumo: | Repeated dosis of inhaled b2-agonists have been used in the treatment of acute asthma. The effect of added ipratropium bromide (IB) to b2-agonist is controversial in adults. OBJECTIVE: To evaluate if addition of IB to fenoterol, in repeated doses, induces a greater bronchodilation, a greater reversion of the attack, and discharge from emergency unit in adults with acute severe asthma. SETTING: Pneumology Emergency Department, UNIFESP-Hospital São Paulo, in the period from July 1995 to February 1997. TYPE OF STUDY: Open, randomized and parallel study. Discharge from the hospital: FEV1 and PEF > 60% of the predicted value. METHODS: 120 patients with FEV1 and PEF < 50% of the predicted value were divided into two groups (N = 60): fenoterol (F) and ipratropium bromide + fenoterol (IBF). Each group received inhalation treatment through a metered-dose inhaler (MDI) attached to a holding chamber, administered at 30-minute interval, for a total of three treatments. In the group F four puffs of fenoterol (400 mg) were administered, and in the IBF group, 160 mg of BI and 400 mg of fenoterol (four puffs). RESULTS: The patients did not differ from basal PEF (F = 36 ± 7% vs IBF = 35 ± 9% predicted) and basal FEV1 (F = 33 ± 9% vs IBF = 32 ± 9% predicted). Thirty-two patients of group F and 33 of group IBF were discharged from hospital after the inhalation treatment. The final FEV1 and PEF after inhalation treatments were F = 60 ± 13% vs IBF = 61 ± 11% e F = 74 ± 18% vs IBF = 77 ± 13% (NS). CONCLUSION: The addition of ipratropium bromide to fenoterol results in insignificant functional effect and without clinical impact in the treatment of acute asthma in adults. |
id |
UFSP_342293a68b033a7fc838a75f05c6198f |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/860 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultosOpen, controlled clinical assay of the addition of ipratropium bromide to fenoterol in the treatment of acute asthma crisis in adultsFenoterolIpratropiumStatus asthmaticusRespiratory therapyFenoterolN-isopropilatropinaEstado asmáticoTerapia respiratóriaRepeated dosis of inhaled b2-agonists have been used in the treatment of acute asthma. The effect of added ipratropium bromide (IB) to b2-agonist is controversial in adults. OBJECTIVE: To evaluate if addition of IB to fenoterol, in repeated doses, induces a greater bronchodilation, a greater reversion of the attack, and discharge from emergency unit in adults with acute severe asthma. SETTING: Pneumology Emergency Department, UNIFESP-Hospital São Paulo, in the period from July 1995 to February 1997. TYPE OF STUDY: Open, randomized and parallel study. Discharge from the hospital: FEV1 and PEF > 60% of the predicted value. METHODS: 120 patients with FEV1 and PEF < 50% of the predicted value were divided into two groups (N = 60): fenoterol (F) and ipratropium bromide + fenoterol (IBF). Each group received inhalation treatment through a metered-dose inhaler (MDI) attached to a holding chamber, administered at 30-minute interval, for a total of three treatments. In the group F four puffs of fenoterol (400 mg) were administered, and in the IBF group, 160 mg of BI and 400 mg of fenoterol (four puffs). RESULTS: The patients did not differ from basal PEF (F = 36 ± 7% vs IBF = 35 ± 9% predicted) and basal FEV1 (F = 33 ± 9% vs IBF = 32 ± 9% predicted). Thirty-two patients of group F and 33 of group IBF were discharged from hospital after the inhalation treatment. The final FEV1 and PEF after inhalation treatments were F = 60 ± 13% vs IBF = 61 ± 11% e F = 74 ± 18% vs IBF = 77 ± 13% (NS). CONCLUSION: The addition of ipratropium bromide to fenoterol results in insignificant functional effect and without clinical impact in the treatment of acute asthma in adults.No tratamento da crise de asma, empregam-se doses repetidas de drogas b2-agonistas por via inalatória. O efeito da adição do brometo de ipratrópio (BI) ao b2-agonistas é controverso em adultos. OBJETIVO: Avaliar se adição de BI ao fenoterol, em tratamentos inalatórios repetidos, induz a maior broncodilatação, com reversibilidade da crise e alta da emergência em pacientes em crise grave de asma. LOCAL DO ESTUDO: Serviço de Pronto-Atendimento de Pneumologia, Disciplina de Pneumologia da UNIFESP-Hospital São Paulo, no período de julho de 1995 a fevereiro de 1997. TIPO DE ESTUDO: Aberto, randomizado, paralelo. Alta da emergência determinada pelo VEF1 e PFE > 60% do previsto. CASUÍSTICA E MÉTODOS: Cento e vinte pacientes em crise de asma foram divididos em dois grupos (N = 60): fenoterol (F) e brometo de ipratrópio + fenoterol (BIF) com VEF1 e PFE < 50% do previsto. Cada grupo recebeu três tratamentos inalatórios, através de nebulímetro e câmara de expansão, administrados em intervalos de 30 minutos. No grupo F foram administrados 4 jatos de fenoterol (400mcg) e no grupo BIF, 160mcg de BI e 400mcg de fenoterol (4 jatos). RESULTADOS: A média (± DP) do PFE basal (F = 36 ± 7% vs. BIF = 35 ± 9% previsto) e do VEF1 basal (F = 33 ± 9% vs. BIF = 32 ± 9%). Trinta e dois pacientes no grupo F e 33 pacientes no grupo BIF tiveram alta após tratamentos inalatórios. O VEF1 e PFE ao final dos tratamentos inalatórios foram, respectivamente, F = 60 ± 13% vs. BIF = 61 ± 11% e F = 74 ± 18% vs. BIF = 77 ± 13% (NS). CONCLUSÃO: A adição de brometo de ipratrópio ao fenoterol resulta em efeito funcional insignificante e sem impacto clínico no tratamento da crise de asma em adultos.Universidade Federal de São Paulo (UNIFESP) Departamento de EnfermagemUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de MedicinaUNIFESP, Depto. de EnfermagemUNIFESP, EPMSciELOSociedade Brasileira de Pneumologia e TisiologiaUniversidade Federal de São Paulo (UNIFESP)Diccini, Solange [UNIFESP]Silva, Clystenes Odyr Soares [UNIFESP]Nakatani, Jorge [UNIFESP]Pereira, Carlos Alberto de Castro [UNIFESP]2015-06-14T13:24:57Z2015-06-14T13:24:57Z1999-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion301-308application/pdfhttp://dx.doi.org/10.1590/S0102-35861999000600002Jornal de Pneumologia. Sociedade Brasileira de Pneumologia e Tisiologia, v. 25, n. 6, p. 301-308, 1999.10.1590/S0102-35861999000600002S0102-35861999000600002.pdf0102-3586S0102-35861999000600002http://repositorio.unifesp.br/handle/11600/860porJornal de Pneumologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-29T19:08:01Zoai:repositorio.unifesp.br/:11600/860Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:58:02.634651Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos Open, controlled clinical assay of the addition of ipratropium bromide to fenoterol in the treatment of acute asthma crisis in adults |
title |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
spellingShingle |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos Diccini, Solange [UNIFESP] Fenoterol Ipratropium Status asthmaticus Respiratory therapy Fenoterol N-isopropilatropina Estado asmático Terapia respiratória |
title_short |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
title_full |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
title_fullStr |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
title_full_unstemmed |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
title_sort |
Ensaio clínico, aberto, controlado sobre a adição de brometo de ipratrópio ao fenoterol no tratamento da crise de asma em adultos |
author |
Diccini, Solange [UNIFESP] |
author_facet |
Diccini, Solange [UNIFESP] Silva, Clystenes Odyr Soares [UNIFESP] Nakatani, Jorge [UNIFESP] Pereira, Carlos Alberto de Castro [UNIFESP] |
author_role |
author |
author2 |
Silva, Clystenes Odyr Soares [UNIFESP] Nakatani, Jorge [UNIFESP] Pereira, Carlos Alberto de Castro [UNIFESP] |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Diccini, Solange [UNIFESP] Silva, Clystenes Odyr Soares [UNIFESP] Nakatani, Jorge [UNIFESP] Pereira, Carlos Alberto de Castro [UNIFESP] |
dc.subject.por.fl_str_mv |
Fenoterol Ipratropium Status asthmaticus Respiratory therapy Fenoterol N-isopropilatropina Estado asmático Terapia respiratória |
topic |
Fenoterol Ipratropium Status asthmaticus Respiratory therapy Fenoterol N-isopropilatropina Estado asmático Terapia respiratória |
description |
Repeated dosis of inhaled b2-agonists have been used in the treatment of acute asthma. The effect of added ipratropium bromide (IB) to b2-agonist is controversial in adults. OBJECTIVE: To evaluate if addition of IB to fenoterol, in repeated doses, induces a greater bronchodilation, a greater reversion of the attack, and discharge from emergency unit in adults with acute severe asthma. SETTING: Pneumology Emergency Department, UNIFESP-Hospital São Paulo, in the period from July 1995 to February 1997. TYPE OF STUDY: Open, randomized and parallel study. Discharge from the hospital: FEV1 and PEF > 60% of the predicted value. METHODS: 120 patients with FEV1 and PEF < 50% of the predicted value were divided into two groups (N = 60): fenoterol (F) and ipratropium bromide + fenoterol (IBF). Each group received inhalation treatment through a metered-dose inhaler (MDI) attached to a holding chamber, administered at 30-minute interval, for a total of three treatments. In the group F four puffs of fenoterol (400 mg) were administered, and in the IBF group, 160 mg of BI and 400 mg of fenoterol (four puffs). RESULTS: The patients did not differ from basal PEF (F = 36 ± 7% vs IBF = 35 ± 9% predicted) and basal FEV1 (F = 33 ± 9% vs IBF = 32 ± 9% predicted). Thirty-two patients of group F and 33 of group IBF were discharged from hospital after the inhalation treatment. The final FEV1 and PEF after inhalation treatments were F = 60 ± 13% vs IBF = 61 ± 11% e F = 74 ± 18% vs IBF = 77 ± 13% (NS). CONCLUSION: The addition of ipratropium bromide to fenoterol results in insignificant functional effect and without clinical impact in the treatment of acute asthma in adults. |
publishDate |
1999 |
dc.date.none.fl_str_mv |
1999-12-01 2015-06-14T13:24:57Z 2015-06-14T13:24:57Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0102-35861999000600002 Jornal de Pneumologia. Sociedade Brasileira de Pneumologia e Tisiologia, v. 25, n. 6, p. 301-308, 1999. 10.1590/S0102-35861999000600002 S0102-35861999000600002.pdf 0102-3586 S0102-35861999000600002 http://repositorio.unifesp.br/handle/11600/860 |
url |
http://dx.doi.org/10.1590/S0102-35861999000600002 http://repositorio.unifesp.br/handle/11600/860 |
identifier_str_mv |
Jornal de Pneumologia. Sociedade Brasileira de Pneumologia e Tisiologia, v. 25, n. 6, p. 301-308, 1999. 10.1590/S0102-35861999000600002 S0102-35861999000600002.pdf 0102-3586 S0102-35861999000600002 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Jornal de Pneumologia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
301-308 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Pneumologia e Tisiologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Pneumologia e Tisiologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1818379401069330432 |